MiNK Therapeutics, Inc.

NASDAQ:INKT

Biotechnology

Healthcare
$10.22 -2.87%

-$0.35 today

Market cap
$52.17M
Beta
0.47
P/E (TTM)
-4.6
EPS (TTM)
-$2.60
52W Low $6.80High $76.00

Volume 0.01M

Average 0.05M

INKT Other Current Liabilities

Short-term obligations not reported separately, such as accrued expenses.

MiNK Therapeutics, Inc.NASDAQ: INKT

Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026

Other current liabilities rises 48.8% from a year ago

Other current liabilities stood at $3.53M at the end of Q1 FY2026, up 48.8% from a year earlier and down 20.3% from the prior quarter. Over 3 fiscal years it compounded at -18.2% a year.

Context

  • Other current liabilities amounted to 34.0% of total assets at the end of Q1 FY2026, down 21.6 pp from a year earlier.
  • Other current liabilities increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether other current liabilities keeps rising in the next quarterly balance sheet after a +48.8% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.53M-20.3% QoQ
Last fiscal yearDec 2025
$2.85M-19.0% YoY
Year agoMar 2025
$2.37M+48.8% since
Other Current Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+48.8%——
1 year-19.0%——
3-year CAGR-18.2%——
5-year CAGR——
10-year CAGR——

Other Current Liabilities history

USD · from the balance sheet

Latest · FY2025
2.85M USD
Year-over-year change
-19.0%
4-year CAGR
-16.2%

Other Current Liabilities vs competitors

How INKT compares with its peers on the latest reported figures

  • INKT's Mar 2026 other current liabilities of $3.53M is the 2nd highest of the 9 companies compared; the peer median is $463.73K.
  • Its year-over-year change of +48.8% is the highest of 8, against a peer median of -58.0%.
  • Other current liabilities amounts to 34.0% of total assets for INKT, versus a peer median of 1.7%.
INKT Competitors Peer median
Other Current Liabilities for INKT and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
NRXPNRx Pharmaceuticals, Inc.Mar 2026$14.8M -2.1%+691.0%124.3%
INKTMiNK Therapeutics, Inc.Mar 2026$3.53M +48.8%-18.2%34.0%
OTLKOutlook Therapeutics, Inc.Mar 2026$1.24M -4.8%+27.8%5.7%
EQEquillium, Inc.Mar 2026$1.13M -49.7%—1.8%
SPRBSpruce Biosciences, Inc.Mar 2026$640K -58.0%+11.3%1.1%
GANXGain Therapeutics, Inc.Mar 2026$287.47K -75.4%-22.7%1.5%
VTVTvTv Therapeutics Inc.Mar 2026$60K —+40.1%0.1%
HOWLWerewolf Therapeutics, Inc.Jun 2026$0 -100.0%+45.1%0.0%
OSTXOS Therapies IncorporatedMar 2026-$1.34B -69897.9%—18356.0%
Peer median (excluding INKT) $463.73K-58.0%+33.9%1.7%

Competitors are the stored peer set for INKT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents38.89M19.64M3.37M4.58M13.36M
Short-term Investments00000
Net Receivables23K0000
Inventory00000
Other Current Assets721.32K470.3K177.96K164.24K211.2K
Total Current Assets39.63M20.4M3.6M4.99M13.85M
Property, Plant & Equipment (Net)606.6K1.07M953.98K732.93K390.87K
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets00000
Total Non-current Assets606.6K1.07M953.98K732.93K390.87K
Total Assets40.24M21.47M4.55M5.72M14.24M
Account Payables3M5.82M3.91M2.73M3.43M
Short-term Debt00005.18M
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities5.76M5.21M5.66M3.51M2.85M
Total Current Liabilities16.47M12.68M11.4M6.96M13.03M
Long-term Debt0004.92M0
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities09.19M11.21M13.42M15.44M
Total Non-current Liabilities09.19M11.21M18.35M15.44M
Total Liabilities16.47M21.87M22.61M25.31M28.47M
Common Stock3353393464048
Retained Earnings(82.95M)(110.94M)(133.4M)(144.18M)(156.68M)
Accumulated OCI(625.27K)(292.47K)(430.95K)(631.58K)(718.92K)
Other Stockholders Equity0900000
Minority Interest00000
Total Equity23.78M(401.3K)(18.06M)(19.59M)(14.23M)
Total Debt0004.92M5.18M
Net Debt(38.89M)(19.64M)(3.37M)347.57K(8.18M)

MiNK Therapeutics, Inc.

NASDAQ:INKT

Intrinsic Alpha fair value

Locked

Current Price

$10.22

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.